Neoantigen therapies market seen reaching $2.83 billion by 2030

The neoantigen therapies market is projected to jump from $0.96 billion in 2025 to $2.83 billion by 2030 as cancer cases rise and personalized immunotherapy gains traction. North America led the market in 2025, while AI-driven antigen prediction, mRNA platforms and combination therapies are emerging as major growth themes.

Why it matters: - Neoantigen therapies are a personalized cancer treatment approach designed to target tumor-specific mutations while sparing healthy tissue. - The market’s projected growth signals rising demand for precision oncology tools as cancer incidence increases worldwide. - The forecast points to broader clinical adoption of immunotherapies built around genomic sequencing and bioinformatics.

What happened: - The neoantigen therapies market is forecast to rise from $0.96 billion in 2025 to $1.19 billion in 2026. - The market is expected to reach $2.83 billion by 2030. - The Business Research Company published the forecast on July 20, 2026. - The report covers North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company also offered a free sample of the report and the full market report.

The details: - The market is projected to grow at a 24.1% CAGR from 2025 to 2026. - The market is forecast to grow at a 24.3% CAGR through 2030. - Historic growth has been driven by rising cancer rates, next-generation sequencing advances, early adoption of personalized oncology, more immunotherapy clinical trials and better understanding of tumor mutational burden. - Future growth drivers include AI-powered bioinformatics for antigen prediction, more regulatory approvals for personalized cancer vaccines, higher investment in precision oncology, off-the-shelf neoantigen products and wider use of combination immunotherapy. - Key product trends include personalized neoantigen vaccines based on tumor-specific mutations, AI-based neoantigen prediction and epitope mapping, mRNA- and peptide-based individualized immunotherapies, next-generation sequencing for early tumor antigen detection and pairing neoantigen therapies with checkpoint inhibitors. - North America held the largest market share in 2025 and is expected to be the fastest-growing region over the forecast period. - North America’s position is supported by advanced healthcare infrastructure, biotech investment and regulatory support for personalized cancer treatments.

Between the lines: - The market outlook reflects a shift from broad cancer immunotherapy toward highly individualized treatments built around each patient’s tumor profile. - The size of the forecast suggests investors and drug developers are betting on platforms that can scale personalization through automation, AI and standardized manufacturing. - The WHO projected in February 2024 that global cancer cases could exceed 35 million by 2050, up 77% from about 20 million in 2022. - That rising disease burden helps explain why precision therapies aimed at specific mutations are attracting more attention.

What's next: - Developers are likely to focus on improving antigen prediction, speeding vaccine design and expanding combination regimens with checkpoint inhibitors. - More clinical and regulatory activity is expected around personalized cancer vaccines and individualized immunotherapies. - The report says future market growth will also depend on advances in off-the-shelf neoantigen products.

The bottom line: - Neoantigen therapies are moving from a niche research area toward a larger precision-oncology market, with demand rising fastest where cancer incidence, sequencing tools and biotech investment are all increasing.